TAIPEI, March 17, 2025 /PRNewswire/ -- Microbio Co., Ltd. (TPEx: 4128) today announced promising results from an exploratory clinical trial assessing MS-20 in combination with current medications for ...
Visit a quote page and your recently viewed tickers will be displayed here.
Microbio (4128) has delivered a -38.41% change over the past year, with a 52-week range between 17.90 and 35.65. What Is the Average Daily Trading Volume of Microbio (4128)? The average daily trading ...
BRISBANE, Australia, Nov. 29, 2024 /PRNewswire/ -- Microbio Ltd, the Australian pathogen diagnostics company specialising in innovative molecular diagnostic solutions, has appointed Paul Brennan as ...
Leo Pharma is paying $40 million upfront and $530 million in biobucks to license a midstage experimental eczema and asthma drug. The therapy, FB825, has been developed by Oneness Biotech and Microbio ...
BALLERUP, Denmark--(BUSINESS WIRE)--LEO Pharma A/S, a global leader in medical dermatology, today announced that is has signed a worldwide exclusive licensing agreement with Oneness Biotech (Taiwan, ...
Brisbane medtech scale-up Microbio has developed a game-changing pathogen test to help identify “a silent killer” that is notoriously difficult to predict, diagnose and treat, as the signs and ...
Microbio (Shanghai) Co. Ltd. has synthesized glucagon-like peptide 1 receptor (GLP1R) agonists reported to be useful for the treatment of obesity, type 2 diabetes and nonalcoholic fatty liver disease.
Microbio Co., Ltd. researches, develops, manufactures, and trades in biotech drugs and dietary supplements in Taiwan. The company provides MS-20 for fatigue and appetite loss associated with cancer ...
4147.TWO TaiMed Biologics Inc.
Microbio Co., Ltd. researches, develops, manufactures, and trades in biotech drugs and dietary supplements in Taiwan. The company provides MS-20 for fatigue and appetite loss associated with cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results